美国在台协会机制:洞察2021。

Allergologie Select Pub Date : 2022-11-21 eCollection Date: 2022-01-01 DOI:10.5414/ALX02300E
Pattraporn Satitsuksanoa, Alba Angelina, Oscar Palomares, Mübeccel Akdis
{"title":"美国在台协会机制:洞察2021。","authors":"Pattraporn Satitsuksanoa,&nbsp;Alba Angelina,&nbsp;Oscar Palomares,&nbsp;Mübeccel Akdis","doi":"10.5414/ALX02300E","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Allergen-specific immunotherapy (AIT) is currently the only treatment with potential long-term disease-modifying effects for patients suffering from allergic diseases such as allergic rhinitis, allergic asthma, venom allergy, or IgE-mediated food allergy. A better understanding of the molecular mechanisms underlying immune responses during successful AIT is of utmost importance and it may help to develop more effective and safer treatments.</p><p><strong>Materials and methods: </strong>PubMed literature review was performed using keywords such as allergen-specific immunotherapy; regulatory T cells; regulatory B cells; regulatory innate lymphoid cells; and allergen-specific antibody from years 2018 to 2021.</p><p><strong>Results: </strong>The proposed mechanism of long-term tolerance induction in AIT, even upon treatment discontinuation, involves basophils, mast cells, innate lymphoid cells, dendritic cells, allergen-specific regulatory T and B cells, downregulation of effector type 2 responses, decrease in the production of IgE and increase in production of allergen-specific blocking antibodies, such as IgG2 and IgG4.</p><p><strong>Conclusion: </strong>We summarize the most recent advances related to mechanisms involved in the restoration of healthy immune responses to allergens during AIT. Our knowledge in this regard has significantly improved over the last years, which might well contribute to design novel and improved therapeutic approaches.</p>","PeriodicalId":7485,"journal":{"name":"Allergologie Select","volume":" ","pages":"259-266"},"PeriodicalIF":0.0000,"publicationDate":"2022-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9707368/pdf/","citationCount":"3","resultStr":"{\"title\":\"Mechanisms in AIT: Insights 2021.\",\"authors\":\"Pattraporn Satitsuksanoa,&nbsp;Alba Angelina,&nbsp;Oscar Palomares,&nbsp;Mübeccel Akdis\",\"doi\":\"10.5414/ALX02300E\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Allergen-specific immunotherapy (AIT) is currently the only treatment with potential long-term disease-modifying effects for patients suffering from allergic diseases such as allergic rhinitis, allergic asthma, venom allergy, or IgE-mediated food allergy. A better understanding of the molecular mechanisms underlying immune responses during successful AIT is of utmost importance and it may help to develop more effective and safer treatments.</p><p><strong>Materials and methods: </strong>PubMed literature review was performed using keywords such as allergen-specific immunotherapy; regulatory T cells; regulatory B cells; regulatory innate lymphoid cells; and allergen-specific antibody from years 2018 to 2021.</p><p><strong>Results: </strong>The proposed mechanism of long-term tolerance induction in AIT, even upon treatment discontinuation, involves basophils, mast cells, innate lymphoid cells, dendritic cells, allergen-specific regulatory T and B cells, downregulation of effector type 2 responses, decrease in the production of IgE and increase in production of allergen-specific blocking antibodies, such as IgG2 and IgG4.</p><p><strong>Conclusion: </strong>We summarize the most recent advances related to mechanisms involved in the restoration of healthy immune responses to allergens during AIT. Our knowledge in this regard has significantly improved over the last years, which might well contribute to design novel and improved therapeutic approaches.</p>\",\"PeriodicalId\":7485,\"journal\":{\"name\":\"Allergologie Select\",\"volume\":\" \",\"pages\":\"259-266\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-11-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9707368/pdf/\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Allergologie Select\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5414/ALX02300E\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergologie Select","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5414/ALX02300E","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

摘要

背景:过敏原特异性免疫疗法(AIT)是目前唯一对变应性疾病(如过敏性鼻炎、过敏性哮喘、蛇毒过敏或ige介导的食物过敏)患者具有潜在长期疾病改善作用的治疗方法。在成功的AIT过程中,更好地了解免疫反应的分子机制是至关重要的,它可能有助于开发更有效和更安全的治疗方法。材料与方法:检索PubMed文献,检索关键词为:过敏原特异性免疫治疗;调节性T细胞;调节性B细胞;调节性先天淋巴样细胞;从2018年到2021年的过敏原特异性抗体。结果:即使停止治疗,AIT患者长期耐受性诱导机制涉及嗜碱性细胞、肥大细胞、先天淋巴样细胞、树突状细胞、过敏原特异性调节性T细胞和B细胞、效应2型反应下调、IgE产生减少和过敏原特异性阻断抗体(如IgG2和IgG4)产生增加。结论:我们总结了AIT患者对过敏原恢复健康免疫反应机制的最新进展。我们在这方面的知识在过去几年中有了显著的提高,这可能有助于设计新颖和改进的治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Mechanisms in AIT: Insights 2021.

Mechanisms in AIT: Insights 2021.

Mechanisms in AIT: Insights 2021.

Mechanisms in AIT: Insights 2021.

Background: Allergen-specific immunotherapy (AIT) is currently the only treatment with potential long-term disease-modifying effects for patients suffering from allergic diseases such as allergic rhinitis, allergic asthma, venom allergy, or IgE-mediated food allergy. A better understanding of the molecular mechanisms underlying immune responses during successful AIT is of utmost importance and it may help to develop more effective and safer treatments.

Materials and methods: PubMed literature review was performed using keywords such as allergen-specific immunotherapy; regulatory T cells; regulatory B cells; regulatory innate lymphoid cells; and allergen-specific antibody from years 2018 to 2021.

Results: The proposed mechanism of long-term tolerance induction in AIT, even upon treatment discontinuation, involves basophils, mast cells, innate lymphoid cells, dendritic cells, allergen-specific regulatory T and B cells, downregulation of effector type 2 responses, decrease in the production of IgE and increase in production of allergen-specific blocking antibodies, such as IgG2 and IgG4.

Conclusion: We summarize the most recent advances related to mechanisms involved in the restoration of healthy immune responses to allergens during AIT. Our knowledge in this regard has significantly improved over the last years, which might well contribute to design novel and improved therapeutic approaches.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信